AAO: Medication could reduce burden of steroid drops for patients

Cynthia Matossian, MD, FACS, ABES, presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.


Cynthia Matossian, MD, FACES, ABES, of Matossian Eye Associates, presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.

The study examined early experiences among cataract surgeons with the use of the injectabcle ophthalmic anti-inflammatory medications.Cynthia Matossian, MD, FACS, ABES presents the highlights of a poster on outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications.

Related Videos
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
EDOF lens tech is evolving to help more patients with intermediate vision
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Ora Europe executive outlines pathway for clinical trials
Treat-to-maintain drug vorolanib ushers in new era for retinal therapy
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
Retinal blood flow biomarkers measured with OCT Doppler
POAG study hope to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma
Predicting optimal treatment regimen for patients with nAMD using machine learning
© 2023 MJH Life Sciences

All rights reserved.